{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:43:46Z","timestamp":1794941026436,"version":"4.9.1"},"reference-count":188,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671066"],"award-info":[{"award-number":["81671066"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974162"],"award-info":[{"award-number":["81974162"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.biopha.2021.111454","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T02:20:01Z","timestamp":1615515601000},"page":"111454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"special_numbering":"C","title":["Mechanism and application of metformin in kidney diseases: An update"],"prefix":"10.1016","volume":"138","author":[{"given":"Anni","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2021.111454_bib1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.biopha.2021.111454_bib2","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.biopha.2021.111454_bib3","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00125-017-4343-y","article-title":"60 years of metformin use: a glance at the past and a look to the future","volume":"60","author":"Marshall","year":"2017","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.biopha.2021.111454_bib4","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: Historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.biopha.2021.111454_bib5","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/FPC.0b013e3283559b22","article-title":"Metformin pathways: pharmacokinetics and pharmacodynamics","volume":"22","author":"Gong","year":"2012","journal-title":"Pharmacogenet. Genom."},{"issue":"3","key":"10.1016\/j.biopha.2021.111454_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/2042018810380215","article-title":"Role of metformin in the management of polycystic ovary syndrome","volume":"1","author":"Lashen","year":"2010","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.biopha.2021.111454_bib7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.numecd.2017.04.009","article-title":"Metformin effects on the heart and the cardiovascular system: a review of experimental and clinical data","volume":"27","author":"Nesti","year":"2017","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2021.111454_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2021.111454_bib9","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3109\/0886022X.2016.1149770","article-title":"Metformin alleviated EMT and fibrosis after renal ischemia-reperfusion injury in rats","volume":"38","author":"Wang","year":"2016","journal-title":"Renal Fail."},{"key":"10.1016\/j.biopha.2021.111454_bib10","article-title":"Metformin protects against cisplatin-induced tubular cell apoptosis and acute kidney injury via AMPK alpha-regulated autophagy induction","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2021.111454_bib11","doi-asserted-by":"crossref","DOI":"10.1159\/000368932","article-title":"Beneficial effects of AMP-activated protein kinase agonists in kidney ischemia-reperfusion: autophagy and cellular stress markers","author":"Decleves","year":"2014","journal-title":"Nephron Exp. Nephrol."},{"issue":"9843","key":"10.1016\/j.biopha.2021.111454_bib12","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0140-6736(11)61454-2","article-title":"Acute kidney injury","volume":"380","author":"Bellomo","year":"2012","journal-title":"Lancet."},{"key":"10.1016\/j.biopha.2021.111454_bib13","first-page":"1","article-title":"KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease","year":"2013","journal-title":"Kidney Int. Suppl."},{"issue":"2","key":"10.1016\/j.biopha.2021.111454_bib14","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am. J. Kidney Dis."},{"issue":"10075","key":"10.1016\/j.biopha.2021.111454_bib15","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet."},{"issue":"4","key":"10.1016\/j.biopha.2021.111454_bib16","first-page":"401","article-title":"Chronic renal disease in Spain: prevalence and related factors in persons with diabetes mellitus older than 64 years","volume":"38","author":"Candela","year":"2018","journal-title":"Nefrolog\u00eda"},{"issue":"2","key":"10.1016\/j.biopha.2021.111454_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrneph.2015.173","article-title":"Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease","volume":"12","author":"Thomas","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"issue":"9","key":"10.1016\/j.biopha.2021.111454_bib18","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1681\/ASN.2015050583","article-title":"Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease","volume":"27","author":"Heyer","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2021.111454_bib19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000421651","article-title":"Genetic heterogeneity of polycystic kidney disease in Europe","volume":"97","author":"Peters","year":"1992","journal-title":"Contrib. Nephrol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib20","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1681\/ASN.2015060648","article-title":"Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease","volume":"27","author":"Hwang","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib21","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"issue":"9981","key":"10.1016\/j.biopha.2021.111454_bib22","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","article-title":"Autosomal dominant polycystic kidney disease: the changing face of clinical management","volume":"385","author":"Ong","year":"2015","journal-title":"Lancet."},{"issue":"10","key":"10.1016\/j.biopha.2021.111454_bib23","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1681\/ASN.2018050493","article-title":"Prevalence estimates of polycystic kidney and liver disease by population sequencing","volume":"29","author":"Lanktree","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.biopha.2021.111454_bib24","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.juro.2010.11.073","article-title":"Urolithiasis through the ages: data on more than 200,000 urinary stone analyses","volume":"185","author":"Knoll","year":"2011","journal-title":"J. Urol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib25","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/jcla.21950","article-title":"Multivariate analyses of urinary calculi composition: a 13-year single-center study","volume":"30","author":"Yang","year":"2016","journal-title":"J. Clin. Lab. Anal."},{"issue":"9","key":"10.1016\/j.biopha.2021.111454_bib26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrurol.2014.194","article-title":"Landmarks in the diagnosis and treatment of renal cell carcinoma","volume":"11","author":"Bhatt","year":"2014","journal-title":"Nat. Rev. Urol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111454_bib27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.urolonc.2011.01.003","article-title":"Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft","volume":"31","author":"Liu","year":"2013","journal-title":"Urol. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2021.111454_bib28","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1097\/PAS.0b013e318299f2d1","article-title":"The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia","volume":"37","author":"Srigley","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"issue":"10","key":"10.1016\/j.biopha.2021.111454_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/S0196-0644(89)80933-3","article-title":"Drug-and toxin-induced rhabdomyolysis","volume":"18","author":"Curry","year":"1989","journal-title":"Ann. Emerg. Med."},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib30","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1172\/JCI114386","article-title":"Glomerular hemodynamics in established glycerol-induced ARF in the rat","volume":"84","author":"Wolfert","year":"1989","journal-title":"J. Clin. Invesigt."},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib31","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1111\/j.1523-1755.2005.00326.x","article-title":"Geranylgeranylacetone ameliorates ischemic acute renal failure via induction of Hsp70","volume":"67","author":"Suzuki","year":"2005","journal-title":"Kidney Int."},{"issue":"10","key":"10.1016\/j.biopha.2021.111454_bib32","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/ki.2010.11","article-title":"Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria- dependent pathway","volume":"77","author":"Morales","year":"2010","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.biopha.2021.111454_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00210-010-0572-z","article-title":"Ameliorative effect of flunarizine in cisplatin-induced acute renal failure via mitochondrial permeability transition pore inactivation in rats","volume":"383","author":"Muthuraman","year":"2011","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2021.111454_bib34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tox.2009.11.011","article-title":"Acetaminophen induced renal injury via oxidative stress and TNF- alpha production: therapeutic potential of arjunolic acid","volume":"268","author":"Ghosh","year":"2010","journal-title":"Toxicology"},{"issue":"12","key":"10.1016\/j.biopha.2021.111454_bib35","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.freeradbiomed.2007.08.020","article-title":"Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity","volume":"43","author":"Zhang","year":"2007","journal-title":"Free Radic. Biol. Med."},{"issue":"3","key":"10.1016\/j.biopha.2021.111454_bib36","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1172\/JCI107970","article-title":"The mechanism of acute renal failure after uranyl nitrate","volume":"55","author":"Blantz","year":"1975","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.biopha.2021.111454_bib37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0041-008X(88)90360-2","article-title":"S-(1,2- dichloro- [14C]vinyl) -L-cysteine (DCVC) in the mouse kidney: correlation between tissue-binding and toxicity","volume":"95","author":"Darnerud","year":"1988","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2021.111454_bib38","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/CCM.0b013e31819b5f4e","article-title":"Iloprost preserves renal oxygenation and restores kidney function in endotoxemia-related acute renal failure in the rat","volume":"37","author":"Johannes","year":"2009","journal-title":"Crit. Care. Med."},{"issue":"4","key":"10.1016\/j.biopha.2021.111454_bib39","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/tox.20691","article-title":"The protective effect of erdosteine on radiocontrast induced nephrotoxicity in rats","volume":"26","author":"Yesilyurt","year":"2011","journal-title":"Environ. Toxicol."},{"issue":"1","key":"10.1016\/j.biopha.2021.111454_bib40","doi-asserted-by":"crossref","first-page":"F214","DOI":"10.1152\/ajprenal.00204.2005","article-title":"Impact of genetic background on nephropathy in diabetic mice","volume":"290","author":"Gurley","year":"2006","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"3","key":"10.1016\/j.biopha.2021.111454_bib41","doi-asserted-by":"crossref","first-page":"F788","DOI":"10.1152\/ajprenal.90515.2008","article-title":"Influence of genetic background on albuminuria and kidney injury in Ins2(+\/C96Y) (Akita) mice","volume":"298","author":"Gurley","year":"2010","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib42","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1681\/ASN.2004070612","article-title":"Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db\/db mice","volume":"16","author":"Chow","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"issue":"8","key":"10.1016\/j.biopha.2021.111454_bib43","first-page":"307","article-title":"Hyperlipidemia and renal disease: the use of animal models in understanding pathophysiology and approaches to treatment","volume":"111","author":"Stevenson","year":"1999","journal-title":"Wien Klin. Wochenschr."},{"issue":"3","key":"10.1016\/j.biopha.2021.111454_bib44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/030098588902600302","article-title":"Hereditary polycystic kidney disease associated with osteorenal syndrome in rats","volume":"26","author":"Kaspareit-Rittinghausen","year":"1989","journal-title":"Vet. Pathol."},{"issue":"1","key":"10.1016\/j.biopha.2021.111454_bib45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1538\/expanim.49.51","article-title":"Characterization of a novel polycystic kidney rat model with accompanying polycystic liver","volume":"49","author":"Katsuyama","year":"2000","journal-title":"Exp. Anim."},{"issue":"7","key":"10.1016\/j.biopha.2021.111454_bib46","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1681\/ASN.V17980","article-title":"A hereditary model of slowly progressive polycystic kidney disease in the mouse","volume":"1","author":"Takahashi","year":"1991","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.biopha.2021.111454_bib47","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/ki.1993.151","article-title":"Juvenile cystic kidneys (jck): a new mouse mutation which causes polycystic kidneys","volume":"43","author":"Atala","year":"1993","journal-title":"Kidney Int."},{"issue":"18","key":"10.1016\/j.biopha.2021.111454_bib48","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1093\/hmg\/9.18.2617","article-title":"A human PKD1 transgene generates functional polycystin-1 in mice and is associated with a cystic phenotype","volume":"9","author":"Pritchard","year":"2000","journal-title":"Hum. Mol. Genet."},{"issue":"15","key":"10.1016\/j.biopha.2021.111454_bib49","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/hmg\/11.15.1731","article-title":"Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant","volume":"11","author":"Muto","year":"2002","journal-title":"Hum. Mol. Genet."},{"issue":"21","key":"10.1016\/j.biopha.2021.111454_bib50","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1093\/hmg\/10.21.2385","article-title":"Comparison of Pkd1-targeted mutants reveals that loss of polycystin-1 causes cystogenesis and bone defects","volume":"10","author":"Lu","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.biopha.2021.111454_bib51","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4156075","article-title":"Metformin prevents renal stone formation through an antioxidant mechanism in vitro and in vivo","author":"Yang","year":"2016","journal-title":"Oxid. Med. Cell Longev."},{"issue":"4","key":"10.1016\/j.biopha.2021.111454_bib52","first-page":"1611","article-title":"Metformin prevents nephrolithiasis formation by inhibiting the expression of OPN and MCP-1 in vitro and in vivo","volume":"43","author":"Yang","year":"2019","journal-title":"Int. J. Mol. Med."},{"issue":"11","key":"10.1016\/j.biopha.2021.111454_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079963","article-title":"Endothelin receptor A blockade is an ineffective treatment for adriamycin nephropathy","volume":"8","author":"Tan","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.biopha.2021.111454_bib54","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1078\/0940-2993-00197","article-title":"Temporary warm ischaemia, 5\/6 nephrectomy and single uranyl nitrate administration \u2013 comparison of three models intended to cause renal fibrosis in rats","volume":"53","author":"Appenroth","year":"2001","journal-title":"Exp. Toxicol. Pathol."},{"issue":"3\u20135","key":"10.1016\/j.biopha.2021.111454_bib55","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jsbmb.2006.11.011","article-title":"Therapeutic role and potential mechanisms of active vitamin D in renal interstitial fibrosis","volume":"103","author":"Tan","year":"2007","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2021.111454_bib56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ddmod.2010.08.002","article-title":"Models of chronic kidney disease","volume":"7","author":"Yang","year":"2010","journal-title":"Drug Discov. Today Dis. Models"},{"issue":"5","key":"10.1016\/j.biopha.2021.111454_bib57","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/nrneph.2015.3","article-title":"Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD","volume":"11","author":"Ferenbach","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"issue":"4","key":"10.1016\/j.biopha.2021.111454_bib58","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1681\/ASN.2015030286","article-title":"Targeting endogenous repair pathways after AKI","volume":"27","author":"Humphreys","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.biopha.2021.111454_bib59","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/ki.2011.379","article-title":"Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis","volume":"81","author":"Coca","year":"2012","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib60","doi-asserted-by":"crossref","first-page":"F1346","DOI":"10.1152\/ajprenal.00420.2010","article-title":"Preactivation of AMPK by metformin may ameliorate the epithelial cell damage caused by renal ischemia","volume":"301","author":"Seo-Mayer","year":"2011","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"10","key":"10.1016\/j.biopha.2021.111454_bib61","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/ki.2010.11","article-title":"Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway","volume":"77","author":"Morales","year":"2010","journal-title":"Kidney Int."},{"issue":"7","key":"10.1016\/j.biopha.2021.111454_bib62","doi-asserted-by":"crossref","DOI":"10.1111\/jfbc.12836","article-title":"Combinational effect of curcumin and metformin against gentamicin-induced nephrotoxicity: Involvement of antioxidative, anti-inflammatory and antiapoptotic pathway","volume":"43","author":"Cao","year":"2019","journal-title":"J. Food. Biochem."},{"issue":"1","key":"10.1016\/j.biopha.2021.111454_bib63","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ki.2013.559","article-title":"Rictor\/mTORC2 protects against cisplatin-induced tubular cell death and acute kidney injury","volume":"86","author":"Li","year":"2014","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib64","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.etp.2013.01.007","article-title":"Effect of metformin against cisplatin induced acute renal injury in rats: a biochemical and histoarchitectural evaluation","volume":"65","author":"Sahu","year":"2013","journal-title":"Exp. Toxicol. Pathol."},{"issue":"12","key":"10.1016\/j.biopha.2021.111454_bib65","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1681\/ASN.2008111186","article-title":"The role of the mammalian target of rapamycin (mTOR) in renal disease","volume":"20","author":"Lieberthal","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"issue":"21","key":"10.1016\/j.biopha.2021.111454_bib66","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","article-title":"Metformin use and mortality among patients with diabetes and atherothrombosis","volume":"170","author":"Roussel","year":"2010","journal-title":"Arch. Intern. Med."},{"issue":"4","key":"10.1016\/j.biopha.2021.111454_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001076","article-title":"Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register","volume":"2","author":"Ekstrom","year":"2012","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.biopha.2021.111454_bib68","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11606-017-4219-3","article-title":"Mortality associated with metformin versus sulfonylurea initiation: a cohort study of veterans with diabetes and chronic kidney disease","volume":"33","author":"Marcum","year":"2018","journal-title":"J. Gen. Intern. Med."},{"issue":"5","key":"10.1016\/j.biopha.2021.111454_bib69","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/dom.13642","article-title":"Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease","volume":"21","author":"Charytan","year":"2019","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.biopha.2021.111454_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2019.13206","article-title":"Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function","volume":"322","author":"Roumie","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.biopha.2021.111454_bib71","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.mayocp.2019.07.017","article-title":"A safety comparison of metformin vs sulfonylurea initiation in patients with type 2 diabetes and chronic kidney disease: a retrospective cohort study","volume":"95","author":"Whitlock","year":"2020","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.biopha.2021.111454_bib72","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/M16-1901","article-title":"Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review","volume":"166","author":"Crowley","year":"2017","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib73","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1042\/CS20110386","article-title":"Cellular and molecular mechanisms of metformin: an overview","volume":"122","author":"Viollet","year":"2012","journal-title":"Clin. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib74","first-page":"423","article-title":"Bright renoprotective properties of metformin: beyond blood glucose regulatory effects","volume":"7","author":"Nasri","year":"2013","journal-title":"Iran J. Kidney Dis."},{"issue":"3","key":"10.1016\/j.biopha.2021.111454_bib75","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cbi.2011.03.014","article-title":"Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression","volume":"192","author":"Alhaider","year":"2011","journal-title":"Chem. Biol. Interact."},{"issue":"12","key":"10.1016\/j.biopha.2021.111454_bib76","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0032-1321878","article-title":"Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression","volume":"44","author":"Ishibashi","year":"2012","journal-title":"Horm. Metab. Res."},{"issue":"12","key":"10.1016\/j.biopha.2021.111454_bib77","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1007\/s00125-011-2311-5","article-title":"Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status","volume":"54","author":"Stephenne","year":"2011","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.biopha.2021.111454_bib78","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/sj.emboj.7600110","article-title":"LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK\/PAR-1","volume":"23","author":"Lizcano","year":"2004","journal-title":"EMBO J."},{"issue":"7","key":"10.1016\/j.biopha.2021.111454_bib79","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1172\/JCI40671","article-title":"Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1\/AMPK pathway via a decrease in hepatic energy state","volume":"120","author":"Foretz","year":"2010","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.biopha.2021.111454_bib80","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/jcp.25598","article-title":"Nephroprotective e\ufb00ects of metformin in diabetic nephropathy","volume":"232","author":"Ravindran","year":"2017","journal-title":"J. Cell Physiol."},{"issue":"Pt 1","key":"10.1016\/j.biopha.2021.111454_bib81","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1113\/jphysiol.2006.108506","article-title":"Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders","volume":"574","author":"Viollet","year":"2006","journal-title":"J. Physiol."},{"issue":"5","key":"10.1016\/j.biopha.2021.111454_bib82","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1096\/fj.201901900R","article-title":"Activation of AMP-activated protein kinase during sepsis\/inflammation improves survival by preserving cellular metabolic fitness","volume":"34","author":"Jin","year":"2020","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.biopha.2021.111454_bib83","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/dom.12812","article-title":"Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes","volume":"19","author":"Wu","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"7795","key":"10.1016\/j.biopha.2021.111454_bib84","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-019-1911-y","article-title":"GDF15 mediates the e\ufb00ects of metformin on body weight and energy balance","volume":"578","author":"Coll","year":"2020","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.biopha.2021.111454_bib85","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/dom.12764","article-title":"Metformin-associated risk of acute dialysis in patients with type 2 diabetes: a nationwide cohort study","volume":"18","author":"Carlson","year":"2016","journal-title":"Diabetes Obes Metab."},{"issue":"8","key":"10.1016\/j.biopha.2021.111454_bib86","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(15)00123-0","article-title":"Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study","volume":"3","author":"Hung","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2021.111454_bib87","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3892\/etm.2017.4475","article-title":"Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes","volume":"14","author":"Zhang","year":"2017","journal-title":"Exp. Ther. Med."},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib88","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0188-4409(00)00241-1","article-title":"The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus","volume":"31","author":"Amador-Licona","year":"2000","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.biopha.2021.111454_bib89","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6462793","article-title":"Metformin regulating miR-34a pathway to inhibit Egr1 in rat mesangial cells cultured with high glucose","author":"Wu","year":"2018","journal-title":"Int. J. Endocrinol."},{"issue":"12","key":"10.1016\/j.biopha.2021.111454_bib90","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.4161\/15548627.2014.984270","article-title":"Autophagy inhibition uncovers the neurotoxic action of the antipsychotic drug olanzapine","volume":"10","author":"Vucicevic","year":"2014","journal-title":"Autophagy"},{"issue":"2","key":"10.1016\/j.biopha.2021.111454_bib91","doi-asserted-by":"crossref","first-page":"F617","DOI":"10.1152\/ajprenal.00278.2006","article-title":"A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy","volume":"292","author":"Lee","year":"2007","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"3","key":"10.1016\/j.biopha.2021.111454_bib92","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2337\/db10-0655","article-title":"Tubular injury in a rat model of type 2 diabetes is prevented by metformin","volume":"60","author":"Takiyama","year":"2011","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib93","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40620-015-0258-1","article-title":"Metformin modulates apoptosis and cell signaling of human podocytes under high glucose conditions","volume":"29","author":"Langer","year":"2016","journal-title":"J. Nephrol."},{"key":"10.1016\/j.biopha.2021.111454_bib94","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/210821","article-title":"Renal podocyte injury in a rat model of type 2 diabetes is prevented by metformin","author":"Kim","year":"2012","journal-title":"Exp. Diabetes. Res."},{"issue":"14","key":"10.1016\/j.biopha.2021.111454_bib95","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003247","article-title":"Comparison of acarbose and metformin on albumin excretion in patients with newly diagnosed type 2 diabetes: a randomized controlled trial","volume":"95","author":"Pan","year":"2016","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.biopha.2021.111454_bib96","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1096\/fj.201800529RR","article-title":"Metformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activity","volume":"33","author":"Polianskyte-Prause","year":"2019","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.biopha.2021.111454_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2019.165610","article-title":"Metformin reduces TRPC6 expression through AMPK activation and modulates cytoskeleton dynamics in podocytes under diabetic conditions","volume":"1866","author":"Szrejder","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"8","key":"10.1016\/j.biopha.2021.111454_bib98","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1681\/ASN.2013050527","article-title":"MicroRNA-29a promotion of nephrin acetylation ameliorates hyperglycemia-induced podocyte dysfunction","volume":"25","author":"Lin","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111454_bib99","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000316056","article-title":"Renoprotection by rosiglitazone in accelerated type 2 diabetic nephropathy: role of STAT1 inhibition and nephrin restoration","volume":"32","author":"Tang","year":"2010","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.biopha.2021.111454_bib100","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/340645","article-title":"The ethanol extract of Zingiber zerumbet attenuates streptozotocin-induced diabetic nephropathy in rats","author":"Tzeng","year":"2013","journal-title":"Evid. Based Complement Altern. Med."},{"issue":"5","key":"10.1016\/j.biopha.2021.111454_bib101","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/1753-0407.12437","article-title":"Metformin ameliorates podocyte damage by restoring renal tissue nephrin expression in type 2 diabetic rats","volume":"9","author":"Zhai","year":"2017","journal-title":"J. Diabetes"},{"issue":"8","key":"10.1016\/j.biopha.2021.111454_bib102","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1039\/C4FO00340C","article-title":"Grape seed proanthocyanidin extracts ameliorate podocyte injury by activating peroxisome proliferator-activated receptor-gamma coactivator 1alpha in low-dose streptozotocin-and high-carbohydrate\/high-fat diet-induced diabetic rats","volume":"5","author":"Bao","year":"2014","journal-title":"Food Funct."},{"issue":"10","key":"10.1016\/j.biopha.2021.111454_bib103","first-page":"1059","article-title":"Signaling pathways in diabetic nephropathy","volume":"31","author":"Kawanami","year":"2016","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.biopha.2021.111454_bib104","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.abb.2015.08.009","article-title":"Metformin ameliorates lipotoxicity-induced mesangial cell apoptosis partly via upregulation of glucagon like peptide-1 receptor (GLP-1R)","volume":"584","author":"Kim","year":"2015","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.biopha.2021.111454_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2019.110628","article-title":"Metformin alleviates oxidative stress and enhances autophagy in diabetic kidney disease via AMPK\/SIRT1-FoxO1 pathway","author":"Ren","year":"2020","journal-title":"Mol. Cell Endocrinol."},{"issue":"5","key":"10.1016\/j.biopha.2021.111454_bib106","doi-asserted-by":"crossref","first-page":"F1563","DOI":"10.1152\/ajprenal.90302.2008","article-title":"Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy","volume":"295","author":"Verzola","year":"2008","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"8","key":"10.1016\/j.biopha.2021.111454_bib107","doi-asserted-by":"crossref","first-page":"C621","DOI":"10.1152\/ajpcell.00096.2014","article-title":"Impact of ER stress-regulated ATF4\/p16 signaling on the premature senescence of renal tubular epithelial cells in diabetic nephropathy","volume":"308","author":"Liu","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.biopha.2021.111454_bib108","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8708236","article-title":"Metformin reduces the senescence of renal tubular epithelial cells in diabetic nephropathy via the MBNL1\/miR-130a-3p\/STAT3 pathway","author":"Jiang","year":"2020","journal-title":"Oxid. Med. Cell Longev."},{"key":"10.1016\/j.biopha.2021.111454_bib109","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5280514","article-title":"The alcohol extract of Coreopsis tinctoria Nutt ameliorates diabetes and diabetic nephropathy in db\/db mice through miR1109-192\/miR-200b and PTEN\/AKT and ZEB2\/ECM pathways","author":"Yu","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.biopha.2021.111454_bib110","article-title":"Metformin rescues Parkin protein expression and mitophagy in high glucose-challenged human renal epithelial cells by inhibiting NF-\u03baB via PP2A activation","author":"Zhao","year":"2020","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib111","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"36","key":"10.1016\/j.biopha.2021.111454_bib112","doi-asserted-by":"crossref","first-page":"26159","DOI":"10.1074\/jbc.M606045200","article-title":"AMP-activated kinase inhibits the epithelial Na+ channel through functional regulation of the ubiquitin ligase Nedd4-2","volume":"281","author":"Bhalla","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2021.111454_bib113","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00424-009-0660-4","article-title":"AMPK controls epithelial Na(+) channels through Nedd4-2 and causes an epithelial phenotype when mutated","volume":"458","author":"Alma\u00e7a","year":"2009","journal-title":"Pflugers Arch."},{"issue":"18","key":"10.1016\/j.biopha.2021.111454_bib114","doi-asserted-by":"crossref","first-page":"17608","DOI":"10.1074\/jbc.M501770200","article-title":"Epithelial sodium channel inhibition by AMP-activated protein kinase in oocytes and polarized renal epithelial cells","volume":"280","author":"Carattino","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2021.111454_bib115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3181\/0807-RM-215","article-title":"Structural and functional analyses of liver cysts from the BALB\/c-cpk mouse model of polycystic kidney disease","volume":"234","author":"Muchatuta","year":"2009","journal-title":"Exp. Biol. Med."},{"issue":"4","key":"10.1016\/j.biopha.2021.111454_bib116","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00424-002-0957-z","article-title":"cAMP-dependent activation of CFTR inhibits the epithelial sodium channel (ENaC) without affecting its surface expression","volume":"445","author":"Konstas","year":"2003","journal-title":"Pflugers Arch."},{"issue":"11","key":"10.1016\/j.biopha.2021.111454_bib117","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/embo-reports\/kve232","article-title":"The cystic fibrosis transmembrane conductance regulator (CFTR) inhibits ENaC through an increase in the intracellular CI- concentration","volume":"2","author":"K\u00f6nig","year":"2001","journal-title":"EMBO Rep."},{"issue":"3","key":"10.1016\/j.biopha.2021.111454_bib118","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbadis.2006.11.006","article-title":"Regulated ion transport in mouse liver cyst epithelial cells","volume":"1772","author":"Doctor","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"5","key":"10.1016\/j.biopha.2021.111454_bib119","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bph.14558","article-title":"The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease","volume":"176","author":"Lian","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2021.111454_bib120","article-title":"Low-dose 2-deoxyglucose and metformin synergically inhibit proliferation of human polycystic kidney cells by modulating glucose metabolism","author":"Zhao","year":"2019","journal-title":"Cell Death Discov."},{"issue":"8","key":"10.1016\/j.biopha.2021.111454_bib121","first-page":"1591","article-title":"Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin","volume":"466","author":"Mekahli","year":"2014","journal-title":"Pflugers Arch."},{"issue":"1","key":"10.1016\/j.biopha.2021.111454_bib122","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1038\/s41598-017-07300-x","article-title":"Metformin inhibits cyst formation in a zebrafish model of polycystin-2 deficiency","volume":"7","author":"Chang","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2021.111454_bib123","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/hmg\/ddn384","article-title":"Zebrafish Tsc1 reveals functional interactions between the cilium and the TOR pathway","volume":"18","author":"DiBella","year":"2009","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib124","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.ejca.2012.10.027","article-title":"Renal tumours in a Tsc1+\/\u2212 mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin","volume":"49","author":"Yang","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2021.111454_bib125","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-020-0285-0","article-title":"Metformin effectively treats Tsc1 deletion-caused kidney pathology by upregulating AMPK phosphorylation","author":"Fang","year":"2020","journal-title":"Cell Death Discov."},{"issue":"5","key":"10.1016\/j.biopha.2021.111454_bib126","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000488807","article-title":"A randomized clinical trial of metformin to treat autosomal dominant polycystic kidney disease","volume":"47","author":"Seliger","year":"2018","journal-title":"Am. J. Nephrol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib127","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/14728222.2020.1751818","article-title":"New insights into targeting hepatic cystogenesis in autosomal dominant polycystic liver and kidney disease","volume":"24","author":"Barten","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"issue":"1","key":"10.1016\/j.biopha.2021.111454_bib128","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12882-019-1463-2","article-title":"A single-arm pilot study of metformin in patients with autosomal dominant polycystic kidney disease","volume":"20","author":"Sorohan","year":"2019","journal-title":"BMC Nephrol."},{"issue":"1","key":"10.1016\/j.biopha.2021.111454_bib129","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12882-018-1090-3","article-title":"Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?","volume":"19","author":"Pisani","year":"2018","journal-title":"BMC Nephrol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib130","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0302-2838(03)00415-9","article-title":"Study on the prevalence and incidence of urolithiasis in Germany comparing the years 1979 vs. 2000","volume":"44","author":"Hesse","year":"2003","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111454_bib131","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.urology.2007.09.034","article-title":"Prevalence and epidemiological characteristics of urolithiasis in Japan: National Trends Between 1965 and 2005","volume":"71","author":"Yasui","year":"2008","journal-title":"Urology"},{"issue":"7","key":"10.1016\/j.biopha.2021.111454_bib132","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1464-410X.2011.10495.x","article-title":"Trends in urological stone disease","volume":"109","author":"Turney","year":"2012","journal-title":"BJU Int."},{"issue":"3","key":"10.1016\/j.biopha.2021.111454_bib133","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.juro.2012.05.078","article-title":"Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations","volume":"189","author":"Khan","year":"2013","journal-title":"J. Urol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib134","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1053\/ajkd.1998.v31.pm9631856","article-title":"Chemotactic factors and renal inflammation","volume":"31","author":"Rovin","year":"1998","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.biopha.2021.111454_bib135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/01.ASN.0000040593.93815.9D","article-title":"Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules","volume":"14","author":"Wesson","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2021.111454_bib136","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.2741\/1347","article-title":"Modulators of urinary stone formation","volume":"9","author":"Khan","year":"2004","journal-title":"Front. Biosci."},{"issue":"1","key":"10.1016\/j.biopha.2021.111454_bib137","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.pharmthera.2011.09.004","article-title":"Metformin and neoplasia: Implications and indications","volume":"133","author":"Aljada","year":"2012","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.biopha.2021.111454_bib138","doi-asserted-by":"crossref","DOI":"10.2741\/4484","article-title":"Metformin suppresses CRC growth by inducing apoptosis via ADORA1","author":"Lan","year":"2017","journal-title":"Front. Biosci."},{"key":"10.1016\/j.biopha.2021.111454_bib139","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ctrv.2017.01.005","article-title":"Combination of metformin with chemotherapeutic drugs via different molecular mechanisms","volume":"54","author":"Peng","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.biopha.2021.111454_bib140","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/CEJ.0000000000000246","article-title":"Metformin and the risk of renal cell carcinoma: a case-control analysis","volume":"26","author":"Becker","year":"2017","journal-title":"Eur. J. Cancer Prev."},{"issue":"11\u201312","key":"10.1016\/j.biopha.2021.111454_bib141","doi-asserted-by":"crossref","first-page":"E687","DOI":"10.5489\/cuaj.1447","article-title":"The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma","volume":"7","author":"Hakimi","year":"2013","journal-title":"Can. Urol. Assoc. J."},{"issue":"Pt A","key":"10.1016\/j.biopha.2021.111454_bib142","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.phrs.2016.09.027","article-title":"Medication use and survival in diabetic patients with kidney cancer: a population-based cohort study","volume":"113","author":"Nayan","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.biopha.2021.111454_bib143","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.urolonc.2014.07.008","article-title":"The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma","volume":"33","author":"Psutka","year":"2015","journal-title":"Urol. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111454_bib144","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.clgc.2015.12.012","article-title":"Metformin use in relation with survival outcomes of patients with renal cell carcinoma","volume":"14","author":"Cheng","year":"2016","journal-title":"Clin. Genitourin. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2021.111454_bib145","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.clgc.2016.06.017","article-title":"Effect of metformin use on survival outcomes in patients with metastatic renal cell carcinoma","volume":"15","author":"Hamieh","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2021.111454_bib146","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.clgc.2016.04.012","article-title":"Metformin use and outcome of Sunitinib treatment in patients with diabetes and metastatic renal cell carcinoma","volume":"14","author":"Keizman","year":"2016","journal-title":"Clin. Genitourin. Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2021.111454_bib147","first-page":"1865","article-title":"A large cohort study of nonsteroidal anti-inflammatory drugs and renal cell carcinoma incidence in the National Institutes of Health-AARP Diet and Health Study","volume":"24","author":"Liu","year":"2013","journal-title":"Cancer Causes Control"},{"issue":"11","key":"10.1016\/j.biopha.2021.111454_bib148","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.4161\/cbt.10.11.13629","article-title":"AMPK as a therapeutic target in renal cell carcinoma","volume":"10","author":"Woodard","year":"2010","journal-title":"Cancer Biol. Ther."},{"issue":"9","key":"10.1016\/j.biopha.2021.111454_bib149","first-page":"1504","article-title":"Effect of metformin on apoptosis of renal cell carcinoma cells in vitro and its mechanisms","volume":"31","author":"Li","year":"2011","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"10.1016\/j.biopha.2021.111454_bib150","doi-asserted-by":"crossref","first-page":"29","DOI":"10.12659\/MSM.898710","article-title":"Metformin induces growth inhibition and cell cycle arrest by upregulating microRNA34a in renal cancer cells","volume":"23","author":"Xie","year":"2017","journal-title":"Med. Sci. Monit."},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib151","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.3892\/mmr.2014.2097","article-title":"Effect of metformin on apoptosis, cell cycle arrest migration and invasion of A498 cells","volume":"9","author":"Fang","year":"2014","journal-title":"Mol. Med. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2021.111454_bib152","first-page":"2030","article-title":"Metformin-induced apoptosis facilitates degradation of the cellular caspase 8 (FLICE)-like inhibitory protein through a caspase-dependent pathway in human renal cell carcinoma A498 cells","volume":"16","author":"Jang","year":"2018","journal-title":"Oncol. Lett."},{"issue":"10","key":"10.1016\/j.biopha.2021.111454_bib153","first-page":"3289","article-title":"Metformin inhibits cell growth by upregulating microRNA-26a in renal cancer cells","volume":"7","author":"Yang","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"3","key":"10.1016\/j.biopha.2021.111454_bib154","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ccr.2014.07.014","article-title":"The somatic genomic landscape of chromophobe renal cell carcinoma","volume":"26","author":"Davis","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2021.111454_bib155","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-1-9","article-title":"Mitochondrial defects in cancer","author":"Carew","year":"2002","journal-title":"Mol. Cancer"},{"issue":"7494","key":"10.1016\/j.biopha.2021.111454_bib156","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature13110","article-title":"Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides","volume":"508","author":"Birsoy","year":"2014","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.biopha.2021.111454_bib157","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.7150\/jca.36372","article-title":"Metformin in combination with JS-K inhibits growth of renal cell carcinoma cells via reactive oxygen species activation and inducing DNA breaks","volume":"11","author":"Zhao","year":"2020","journal-title":"J. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2021.111454_bib158","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cmet.2010.03.014","article-title":"Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner","volume":"11","author":"Kalender","year":"2010","journal-title":"Cell Metab."},{"issue":"7","key":"10.1016\/j.biopha.2021.111454_bib159","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease \u2013 a systematic review and meta-395 analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.biopha.2021.111454_bib160","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.kint.2018.04.011","article-title":"Analysis of the global burden of disease study highlights the global, 457 regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016","volume":"94","author":"Xie","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2021.111454_bib161","series-title":"2018 USRDS annual data report: 448 Epidemiology of kidney disease in the United States","volume":"vol. 450","year":"2019"},{"issue":"1","key":"10.1016\/j.biopha.2021.111454_bib162","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/kisup.2014.21","article-title":"Obesity, oxidative stress, and fibrosis in chronic kidney disease","volume":"4","author":"Sharma","year":"2014","journal-title":"Kidney. Int. Suppl."},{"issue":"5","key":"10.1016\/j.biopha.2021.111454_bib163","doi-asserted-by":"crossref","first-page":"F727","DOI":"10.1152\/ajprenal.00293.2013","article-title":"Induction of AMPK activity corrects early pathophysiological alterations in the subtotal nephrectomy model of chronic kidney disease","volume":"305","author":"Satriano","year":"2013","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.biopha.2021.111454_bib164","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.taap.2018.10.004","article-title":"Metformin attenuates cardiovascular and renal injury in uninephrectomized rats on DOCA-salt: Involvement of AMPK and miRNAs in cardioprotection","volume":"362","author":"Amara","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2021.111454_bib165","doi-asserted-by":"crossref","first-page":"F1229","DOI":"10.1152\/ajprenal.00539.2019","article-title":"Metformin arrests the progression of established kidney disease in the subtotal nephrectomy model of chronic kidney disease","volume":"318","author":"Borges","year":"2020","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"9","key":"10.1016\/j.biopha.2021.111454_bib166","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1681\/ASN.2018010050","article-title":"Phosphorylation of acetyl-CoA carboxylase by AMPK reduces renal fibrosis and is essential for the anti-fibrotic effect of metformin","volume":"29","author":"Lee","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"issue":"10","key":"10.1016\/j.biopha.2021.111454_bib167","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1097\/TP.0000000000002864","article-title":"Metformin attenuates cyclosporine A-induced renal fibrosis in rats","volume":"103","author":"Lin","year":"2019","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.biopha.2021.111454_bib168","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/nep.13430","article-title":"Metformin inhibits TGF-beta 1-induced MCP-1 expression through BAMBI-mediated suppression of MEK\/ERK1\/2 signaling","volume":"24","author":"Liang","year":"2019","journal-title":"Nephrology"},{"issue":"2","key":"10.1016\/j.biopha.2021.111454_bib169","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/ijms17020146","article-title":"Metformin prevents renal fibrosis in mice with unilateral ureteral obstruction and inhibits Ang II-induced ECM production in renal fibroblasts","volume":"17","author":"Shen","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.biopha.2021.111454_bib170","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14141","article-title":"Metformin modulates immune cell infiltration into the kidney during unilateral ureteral obstruction in mice","volume":"7","author":"Christensen","year":"2019","journal-title":"Physiol. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2021.111454_bib171","doi-asserted-by":"crossref","first-page":"F226","DOI":"10.1152\/ajprenal.00495.2014","article-title":"Activation of AMP-activated protein kinase inhibits ER stress and renal fibrosis","volume":"308","author":"Kim","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"5","key":"10.1016\/j.biopha.2021.111454_bib172","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/15563650.2019.1648816","article-title":"Metformin-related lactic acidosis with acute kidney injury: results of a French observational multicenter study","volume":"58","author":"Corchia","year":"2020","journal-title":"Clin. Toxicol."},{"issue":"9","key":"10.1016\/j.biopha.2021.111454_bib173","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrneph.2017.105","article-title":"Diabetes mellitus: complex interplay between metformin, AKI and lactic acidosis","volume":"3","author":"Rhee","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.biopha.2021.111454_bib174","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3545914","article-title":"Lactic acidosis in diabetic population: is metformin implicated? Results of a matched case-control study performed on the type 2 diabetes population of Grenoble Hospital University","author":"Lepelley","year":"2016","journal-title":"J. Diabetes Res."},{"issue":"11","key":"10.1016\/j.biopha.2021.111454_bib175","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/dom.12978","article-title":"Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: a GoDarts study","volume":"19","author":"Connelly","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"8","key":"10.1016\/j.biopha.2021.111454_bib176","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.2337\/dc13-3023","article-title":"Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study","volume":"37","author":"Eppenga","year":"2014","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.biopha.2021.111454_bib177","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00592-016-0836-2","article-title":"Dose-related effects of metformin on acid-base balance and renal function in patients with diabetes who develop acute renal failure: a cross-sectional study","volume":"53","author":"Cucchiari","year":"2016","journal-title":"Acta Diabetol."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2021.111454_bib178","first-page":"45","article-title":"Metformin-associated lactic acidosis requiring hospitalization. a national 10 year survey and a systematic literature review","volume":"17","author":"Renda","year":"2013","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2021.111454_bib179","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2165\/11536790-000000000-00000","article-title":"Lactic acidosis induced by metformin: incidence, management and prevention","volume":"33","author":"Lalau","year":"2010","journal-title":"Drug Saf."},{"issue":"7","key":"10.1016\/j.biopha.2021.111454_bib180","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0953-6205(02)00131-0","article-title":"Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications","volume":"13","author":"Rachmani","year":"2002","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.biopha.2021.111454_bib181","article-title":"Risk of fatal and non-fatal lactic acidosis with metformin use in type 2 diabetes mellitus","volume":"1","author":"Salpeter","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"issue":"11","key":"10.1016\/j.biopha.2021.111454_bib182","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.2337\/dc08-1171","article-title":"Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia","volume":"31","author":"Bodmer","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2021.111454_bib183","series-title":"Metformin Petition Closeout Memorandum from CDER Director","year":"2016"},{"issue":"1","key":"10.1016\/j.biopha.2021.111454_bib184","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/ndt\/gfw411","article-title":"Guideline development g. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL\/min \/1.73 m2)","volume":"32","author":"Farrington","year":"2017","journal-title":"Nephrol. Dial. Transplant"},{"key":"10.1016\/j.biopha.2021.111454_bib185","series-title":"Type 2 Diabetes in Adults: Management","year":"2017"},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2021.111454_bib186","first-page":"S14","article-title":"Standards of Medical Care in Diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care."},{"issue":"6","key":"10.1016\/j.biopha.2021.111454_bib187","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.2337\/dc10-2361","article-title":"Use of metformin in the setting of mild-to-moderate renal insufficiency","volume":"34","author":"Lipska","year":"2011","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.biopha.2021.111454_bib188","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamainternmed.2018.0292","article-title":"Association of metformin use with risk of lactic acidosis across the range of kidney function a community-based cohort study","volume":"178","author":"Lazarus","year":"2018","journal-title":"JAMA Intern. Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221002390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221002390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:19:12Z","timestamp":1760098752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221002390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":188,"alternative-id":["S0753332221002390"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111454","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanism and application of metformin in kidney diseases: An update","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111454","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"111454"}}